Association of air pollution and use of glyceryl trinitrate against angina pectoris: a population-based case-crossover study

• Main Authors: Finnbjornsdottir, Ragnhildur Gudrun, Zoëga, Helga, Olafsson, Orn, Thorsteinsson, Throstur, Rafnsson, Vilhjalmur
• Format: Other/Unknown Material
• Language: English
• Published: BioMed Central Ltd. 2013
• Subjects: Air pollution; Angina pectoris; Coronary disease; Case-crossover; Drug utilization; Nitrogen dioxide; Ozone; Pharmacoepidemiology; Iceland
• Online Access: http://www.ehjournal.net/content/12/1/38

Abstract Background Ambient air pollution has been associated with increased cardiovascular morbidity and mortality. In Reykjavik, Iceland, air pollutant concentrations exceed official health limits several times every year. The aim was to study the association of concentrations of NO 2 , O 3 , PM 10 , and H 2 S in the Reykjavik capital area with the dispensing of anti-angina pectoris medication, glyceryl trinitrate to the inhabitants. Methods Data on daily dispensing of glyceryl trinitrate , were retrieved from the Icelandic Medicines Registry. Data on hourly concentrations of NO 2 , O 3 , PM 10 , and H 2 S were obtained from the Environment Agency of Iceland. A case-crossover design was used, based on the dispensing of glyceryl trinitrate to 5,246 individuals (≥18 years) between 2005 and 2009. Results For every 10 μg/m 3 increase of NO 2 and O 3 3-day mean concentrations, the odds ratio (OR) for daily dispensing of glyceryl trinitrates was 1.136 (95% confidence intervals (CI) 1.069-1.207) and 1.094 (95% CI 1.029-1.163) at lag 0, and OR was 1.096 (95% CI 1.029-1.168) and 1.094 (95% CI 1.028-1.166) at lag 1, respectively. Conclusions These findings suggest that NO 2 and O 3 ambient air concentrations may adversely affect cardiovascular health, as measured by the dispensing of glyceryl trinitrates for angina pectoris. Further, the findings suggest that data on the dispensing of medication may be a valuable health indicator when studying the effect of air pollution on cardiovascular morbidity.